PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24049110-6	2013	We find FK506 treatment inhibits, whereas Fkbp4/5 overexpression promotes, miRNA-mediated stabilization of Ago2 expression.	Tacrolimus	8-13	argonaute RISC catalytic component 2	Homo sapiens	107-111	
24049110-7	2013	Simultaneous treatment with a lysosome inhibitor revealed the accumulation of unloaded Ago2 complexes in FK506-treated cells.	Tacrolimus	105-110	argonaute RISC catalytic component 2	Homo sapiens	87-91	
24049110-5	2013	Pharmacological inhibition of this interaction using FK506 or siRNA-mediated Fkbp4/5 depletion leads to decreased Ago2 protein levels.	Tacrolimus	53-58	argonaute RISC catalytic component 2	Homo sapiens	114-118